Abpro Holdings, Inc.

Abpro Holdings, Inc. is a biotechnology company focused on developing next-generation antibody therapeutics for patients with severe and life-threatening conditions. The company utilizes its proprietary antibody discovery and engineering platforms, DiversImmune and MultiMab, to design multi-specific antibody candidates primarily targeting immuno-oncology, ophthalmology, and infectious diseases. Its core pipeline includes ABP-102, a bispecific T-cell engager targeting HER2 and CD3 for solid tumors such as breast and gastric cancers, and ABP-201, a bispecific candidate designed to inhibit VEGF and ANG-2 to treat vascular diseases of the eye like wet age-related macular degeneration. The company pursues collaborative agreements and licensing partnerships with third-party biopharmaceutical developers, including Celltrion and Abpro Bio, to advance its programs.

The company operates corporate offices in Burlington, Massachusetts, where its principal executive facilities are located. Through territorial and global partnerships, Abpro engages in collaborative development agreements covering worldwide markets, including rights structured across Asia, the Middle East, and the Commonwealth of Independent States.

Summary of the business section of Abpro's latest annual report, written by StockData.

“As of March 30, 2026, we had one full-time employee and two part-time employees.”